Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.55 GBX | -6.06% | +14.81% | -76.87% |
Apr. 30 | EARNINGS AND TRADING: Software Circle & Beximco report higher revenue | AN |
Apr. 30 | Transcript : Shield Therapeutics plc, 2023 Earnings Call, Apr 30, 2024 |
Business Summary
Number of employees: 27
Sales per Business
GBP in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Feraccru
100.0
%
| 2 | 100.0 % | 4 | 100.0 % | +194.08% |
Sales per region
GBP in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
64.3
%
| 0 | 4.0 % | 3 | 64.3 % | +4,611.48% |
Netherlands
32.2
%
| 1 | 59.8 % | 1 | 32.2 % | +58.37% |
Canada
3.4
%
| - | - | 0 | 3.4 % | - |
South Korea
0.1
%
| 1 | 36.2 % | 0 | 0.1 % | -99.09% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Gregory Madison
CEO | Chief Executive Officer | 57 | 21-05-31 |
Santosh Shanbhag
DFI | Director of Finance/CFO | 47 | Jan. 15 |
David Childs
COO | Chief Operating Officer | - | 11-07-31 |
Jackie Mitchell
CTO | Chief Tech/Sci/R&D Officer | - | 11-12-31 |
Investor Relations Contact | - | - | |
General Counsel | - | 15-07-31 | |
Andy Hurley
PRN | Corporate Officer/Principal | - | 23-04-09 |
Paul Spoors
AUD | Comptroller/Controller/Auditor | - | 18-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 18-07-25 | |
Director/Board Member | 66 | 16-01-31 | |
Director/Board Member | 57 | 21-05-09 | |
Karl Lundström
BRD | Director/Board Member | 62 | 21-05-09 |
Founder | 57 | 07-12-31 | |
Gregory Madison
CEO | Chief Executive Officer | 57 | 21-05-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 782,056,367 | 342,710,006 ( 43.82 %) | 0 | 43.82 % |
Company contact information
Shield Therapeutics Plc
Northern Design Centre Baltic Business Quarter
NE8 3DF, Gateshead Quays
+44 1915 118 500
http://www.shieldtherapeutics.comSector
Sales per Business
Sales per region
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-76.87% | 16.12M | |
-1.35% | 103B | |
+8.43% | 101B | |
+4.40% | 23.07B | |
-12.12% | 22.23B | |
-4.36% | 18.05B | |
-39.98% | 17.18B | |
-10.43% | 16.94B | |
+6.50% | 14.07B | |
+38.09% | 12.35B |
- Stock Market
- Equities
- STX Stock
- Company Shield Therapeutics plc